Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 11/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1550913 | 0.85 | FFAR1 (1.00) | FFAR1FFAR4 | |
| SCHEMBL10936594 | 0.83 | MEN1 (0.63) | MEN1KMT2AALDH1A1HTTAGTR1 | |
| SCHEMBL6192203 | 0.81 | MEN1 (0.55) | FFAR1MEN1KMT2AALDH1A1HTT | |
| SCHEMBL12087531 | 0.81 | MEN1 (0.55) | FFAR1MEN1KMT2AALDH1A1HTT | |
| SCHEMBL1550305 | 0.81 | FFAR1 (0.71) | FFAR1FFAR4 | |
| SCHEMBL1550283 | 0.81 | FFAR1 (0.73) | FFAR1FFAR4 | |
| SCHEMBL1550669 | 0.80 | FFAR1 (0.68) | FFAR1FFAR4 | |
| SCHEMBL1550762 | 0.80 | FFAR1 (0.79) | FFAR1ALDH1A1MAPTFFAR4 | |
| SCHEMBL1550939 | 0.80 | FFAR1 (0.71) | FFAR1FFAR4 | |
| SCHEMBL1550692 | 0.80 | FFAR1 (0.71) | FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105152919-A | Compounds for the treatment of metabolic diseases | UNIV SYDDANSK | 2015-12-16 | — | — | CN | disclosed |
| CN-102137836-B | Compounds for the treatment of metabolic disorders | SYDDANSK UNIVERSITET (DK) | 2015-08-26 | — | — | CN | disclosed |
| US-8586607-B2 | Compounds for the treatment of metabolic diseases | SYDDANSK UNIVERSITET (DK) | 2013-11-19 | — | — | US | disclosed |
| US-8586607-B2 | Compounds for the treatment of metabolic diseases | SYDDANSK UNIVERSITET (DK) | 2013-11-19 | — | — | US | disclosed |
| EP-2313360-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | UNIV SYDDANSK (DK) | 2012-09-05 | — | — | EP | disclosed |
| CN-102137836-A | Compounds for the treatment of metabolic disorders | UNIV SYDDANSK | 2011-07-27 | — | — | CN | disclosed |
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET | 2011-06-23 | — | — | US | disclosed |
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET | 2011-06-23 | — | — | US | disclosed |
| EP-2313360-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | Syddansk Universitet (DK) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010012650-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET (DK) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | GPR119, INSR, GPR65 | FFAR1 6/4885MEN1 2306/4885KMT2A 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.